(Q46973482)

27 December 2017

title

A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus (English)

1 reference

27 December 2017

main subject

type 2 diabetes

0 references

randomized experiment

1 reference

Harold Bays

1

1 reference

27 December 2017

Jennifer McElhattan

series ordinal

2

1 reference

27 December 2017

Brian S Bryzinski

series ordinal

3

1 reference

27 December 2017

GALLANT 6 Study Group

series ordinal

4

1 reference

27 December 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

27 December 2017

Diabetes and Vascular Disease Research

published in

1 reference

27 December 2017

volume

4

1 reference

27 December 2017

issue

3

1 reference

27 December 2017

page(s)

181-193

1 reference

27 December 2017

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Lipids and lipoproteins in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Mechanism of action of fibrates on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Effects of fenofibrate on albuminuria in patients with hypertriglyceridemia and/or hyperuricemia: a multicenter, randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2007.039

21 January 2018

Identifiers

DOI

10.3132/DVDR.2007.039

1 reference

27 December 2017

PubMed ID

17907108

1 reference

27 December 2017